Clinical Research Directory

Inclusion Criteria: * Age 19 years or older * Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria * Appropriate candidate for pulmonary rehabilitation * prescribed nintedanib by their treating physician or currently on nintedanib * 6 minute walk distance 50m or more * Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks Exclusion Criteria: * Contraindication to treatment with nintedanib (based on Canadian labeling) * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) * Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% * Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program * Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit * Use of pirfenidone within 4 weeks of screening * Significant emphysema (less than 10% volume on high resolution computed tomography (HRCT) or forced expiratory volume at one second (FEV1)/FVC less than 0.70)